| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11025442 | International Journal of Infectious Diseases | 2018 | 13 Pages |
Abstract
The use of bedaquiline to treat patients with multidrug-resistant tuberculosis (MDR-TB) and end-stage renal disease (ESRD) may raise safety concerns. Currently, no clinical information is available on the use of bedaquiline to treat MDR-TB patients with ESRD. We report the use of bedaquiline to treat two patients with MDR-TB and ESRD. This report highlights the safety and tolerability of bedaquiline as well as the treatment outcome. The use of bedaquiline in patients with ESRD is also discussed.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Seyeon Park, Kyu Min Lee, Insu Kim, Jeongha Mok,